Skip to main content
. Author manuscript; available in PMC: 2009 May 1.
Published in final edited form as: Neurochem Int. 2007 Nov 26;52(6):1068–1075. doi: 10.1016/j.neuint.2007.11.006

Figure 2.

Figure 2

This figure shows bladder urothelial ATP release (i.e. representing total purine release) in normal and spinal cord injured bladders treated with bovine serum albumin [NL (n=8), and SCI (n=6), respectively], and in spinal cord injured bladders treated with BoNT-A (SCI-BTX, n=6) under basal (i.e. figure 2A) and hypoosmotic (i.e. figure 2B) conditions. This figure demonstrates a significant increase in both basal and hypoosmotic evoked urothelial ATP release following spinal cord injury. BoNT-A, however, was only effective in inhibiting hypoosmotic evoked and not basal ATP release in spinal cord injured bladders. *denotes p<0.05 between NL and SCI groups while #denotes p<0.05 between SCI and SCI-BTX groups using the Kruskal-Wallis non-parametric test with Dunn multiple comparison test